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Abstract 
 
Radioimmunoguided surgery (RIGS) utilizes radionuclide-labeled antibodies that 
bind to an epitope specific to certain cancers to detect and image tumors. The Magliery 
lab has developed a good RIGS candidate molecule called 3E8.scFv, which possesses 
many good theranostic properties but clears from the blood too quickly. Studies on the 
covalent attachment of polyethylene glycol molecules (PEGs) to proteins indicate that 
such PEGylation could improve certain theranostic properties in addition to increasing 
the clearance time. 
Generally, however, the effects of PEGylation are poorly understood. My project 
is to study how PEGylation with different types of PEGs affects binding/activity, 
stability, size, and shape with the end-goal of improving 3E8.scFv as a RIGS molecule. I 
have studied PEG-conjugates of 3E8.scFv and 3E8cys.scFv (3E8.scFv with an added free 
cysteine) to characterize both the general behavior of PEGylated proteins and the 
differences between various types of PEGs. 
We can get a preliminary analysis of the effects of PEGylation with SDS 
polyacrylamide gel electrophoresis (PAGE), but for more in-depth characterizations, we 
will use: surface plasmon resonance (SPR) to measure binding; gel filtration 
chromatography to measure size and aggregation; differential static light-scattering 
(DSLS) and differential scanning fluorimetry (DSF) to measure stability; and analytical 
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ultracentrifugation (AUC) and small-angle x-ray scattering (SAXS) to measure 
size/shape. 
Currently, we can non-specifically PEGylate 3E8.scFv via N-hydroxysuccinimide 
(NHS)-ester chemistry at lysines and specifically PEGylate 3E8cys.scFv via maleimide 
chemistry at the added free cysteine. Both processes are verified via SDS-PAGE analysis. 
We have assessed the binding and stability of 3E8.scFv, 3E8cys.scFv, and various PEG-
conjugates of each using SPR and DSF, which indicate little loss in binding or stability 
from a single PEGylation at the cysteine in 3E8cys.scFv or from a low level of 
PEGylation of 3E8.scFv. With extensive characterization of PEGylation, we could 
explain how PEGylation improves theranostic effectiveness and better utilize it to 
improve theranostic proteins like 3E8.scFv. 
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Chapter 1:  Introduction 
 
1.1 Cancer and Radioimmunoguided Surgery (RIGS) 
 Cancer surgery is currently dominated by positron emission tomography (PET), 
computed tomography (CT) and similar scans, which identify cancerous tissue based on 
properties that cancerous tissue exhibits more than other tissue. For example, a PET scan 
shows areas of high metabolism by detecting where fluorodeoxyglucose (18F) (FDG), a 
glucose analog, is metabolized fastest. Cancer fits this category as cancerous cells have 
higher metabolic rates than normal cells and thus digest more FDG, allowing the 
cancerous tissue to be identifiable over the background. The problem with this is that 
other tissues may also exhibit high glucose metabolism, such as the liver and the brain. 
This means that it is often difficult to tell the difference between cancerous tissue and 
healthy tissue that exhibits similar qualities. More importantly, however, the tumor signal 
to background ratio is not as favorable as it could be. It would be ideal if cancerous tissue 
could be differentiated from healthy tissue using a characteristic that only cancerous 
tissue exhibits, thereby eliminating background signal. 
 Dr. Edward Martin, a surgical oncologist at The Ohio State University’s Wexner 
Medical Center, has helped to develop a type of diagnostic and surgical technology called 
radioimmunoguided surgery, or RIGS. This surgery system relies on the above principle: 
detecting cancer based on some characteristic completely unique to cancer. The idea 
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behind RIGS is to use some form of an antibody to target some characteristic of 
cancerous tissue. This antibody or antibody fragment is then radiolabeled with some 
radioisotope that is detectable and has a half-life appropriate to imaging or detection 
before, during, and after surgery. In this way, the surgery can be guided by a radiolabeled 
immunoglobulin molecule, hence the term radioimmunoguided surgery. The labeled 
antibody would be injected into the patient in order to either detect the cancer or to get a 
working image to guide the surgery. The end goal is to have a camera that can convert the 
signal from the radiolabeled antibodies to a visual depiction right in the operating room. 
A probe would also be utilized for quick determinations and confirmations. This RIGS 
method is superior to current cancer surgery technology because, in theory, it allows 
detection of cancer without having as much background. A better signal to background 
outcome will likely result in a higher percentage of negative margins, which could mean 
that the surgical cut is well away from the border of the tumor. (A positive margin means 
that the surgical cut intersects the tumor and a close margin means that the surgical cut is 
very close to the border of the tumor.) A negative margin in surgery is highly correlated 
with survival, as shown in Figure 1. 
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Figure 1. Surgical margins and survival29 
 
 Additionally, RIGS allows real-time imaging and detection during surgery, 
eliminating the often long wait times traditionally seen for obtaining a post-surgery scan 
to make sure the surgeon removed all of the cancerous tissue.1-6 
 
1.2 Monoclonal Antibodies in RIGS 
 While a RIGS characteristic that applies to all cancerous tissue has yet to be 
discovered, there is a disaccharide called Sialyl-Tn that is part of a glycoprotein called 
tumor-associated glycoprotein 72, or TAG-72, in the mucin surrounding many types of 
cancers, especially adenocarcinomas.7-9 A diagram of Sialyl-Tn and TAG-72 (labeled 
“mucin”) is shown in Figure 2. 
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Figure 2. Diagram of Sialyl-Tn and TAG-72 in cell membrane 
 
 Monoclonal antibodies against Sialyl-Tn have been developed. The first such 
antibody was a full-length mouse antibody called B72.3.8 This antibody, when moved 
into human trials, elicited the human anti-mouse antibodies response, or HAMA 
response.10 The binding of B72.3 was improved in the next generation family of 
antibodies called CC49. However, CC49 still elicited the HAMA response, prompting a 
re-engineering of the scaffolding, resulting in a humanized version of CC49 called 
AKA.11-14 Yoon et al. further advanced antibody design in this field by optimizing 
binding and then back-engineering AKA to a full-length antibody using human 
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scaffolding, resulting in a stronger-binding, more stable monoclonal antibody compatible 
with the RIGS system called 3E8.15-17 A schematic describing antibodies and their 
fragments and showing the progression of TAG-72 monoclonal antibodies that have been 
developed for RIGS is shown in Figure 3. 
 
 
Figure 3. Antibodies and fragments and TAG-72 antibody progression 
 
 As hinted at in Figure 3, the Magliery lab took the full-length IgG 3E8 developed 
by Yoon et al. and engineered it into a single-chain variable fragment, or scFv. It is this 
molecule, 3E8.scFv, on which the work in this thesis is centered. 3E8.scFv is about 28 
kD, composed of two chains, a variable heavy and a variable light chain linked together 
by a string of amino acids, resulting in a single protein that mimics the tip of the full-
length IgG. The problem with 3E8.scFv lies in the fact that it is too small. When injected 
into mice, it is cleared by the kidneys and excreted too quickly to see significant exposure 
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to the cancerous tissue, which would allow it to bind and thus be used for detecting and 
imaging of the tumor. One way of making 3E8.scFv larger is by attaching a polyethylene 
glycol polymer, called a PEG. The problem with this is that, aside from a basic increase 
in size due to the added PEG, the exact effects of PEGylation, namely, structure function 
relationships, are not extensively studied, particularly in the case of antibody fragments. 
So, with the end goal of using 3E8.scFv as a RIGS theranostic molecule, PEGylation will 
be studied. 
 
1.3 Polyethylene Glycol Polymers (PEG) 
 Polyethylene glycol (PEG) is a polymer with the general structure H-(O-CH2-
CH2)n-OH, shown in Figure 4. 
 
 
Figure 4. Basic structure of polyethylene glycol 
 
 PEGs can easily be created with various structures, meaning that its uses are 
myriad. There exist also many PEG derivatives that can be engineered for a host of 
applications. PEGs most commonly appear as the single, linear polymer of varying 
lengths. Recently, however, PEG derivatives that are branched, charged, and activated 
with various functional groups (for attachment to other molecules) are becoming more 
common. The classic production method is via polymerization, which is stopped at a 
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certain extent to create PEGs of a certain length. This creates PEGs that are referred to as 
polydisperse, meaning that the resulting mixture is not homogenous, but contains a 
mixture of PEG molecules of various, but similar lengths, with an average molecular 
weight. The degree of deviation from the average molecular weight can be characterized 
with something called the polydispersity index, which is the ratio of the average 
molecular weight of the mixture divided by the target molecular weight based on number 
of polymer units. Recently, production via polymerization has gotten more precise, 
resulting in much lower polydispersity indices.  
 Regardless, a company in Powell, Ohio, called Quanta BioDesign, has recently 
pioneered a different approach for producing PEGs. Quanta synthesizes PEGs and PEG 
derivatives from pure basic compounds via a series of step-wise reactions, producing 
discrete molecular weight compounds with specific structures and functional groups. 
Whether this accuracy in size is necessary or makes a difference in the various 
applications of PEGs remains to be seen. 
 PEGs are highly soluble in water and are non-immunogenic, meaning they do not 
elicit any immune response in human subjects. For these reasons, PEGs are commonly 
used to modify proteins and other molecules, especially in therapeutic and diagnostic 
(theranostic) roles.  
 
1.4 PEGylation and Theranostic Proteins 
 The process of covalently attaching a PEG structure to another, usually larger 
molecule, like a protein, is referred to as PEGylation. (For simplicity, only the 
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PEGylation of proteins will be discussed here.) PEGylation to proteins can be 
accomplished using a variety of functional group and target residue pairs, especially NHS 
esters with lysine residues and maleimides with cysteine residues. These functional 
groups are attached to the PEGs during production and, usually, using a simple reaction 
setup, can be used to attach their PEGs to the target protein. The chemical reaction 
between an NHS-ester activated PEG and an amine, like a lysine, is shown in Figure 5. 
The corresponding chemical reaction between a maleimide activated PEG and a thiol, 
like a cysteine, is shown in Figure 6.  
 
 
Figure 5. Reaction between an NHS-ester and an amine (Lys) 
 
 
Figure 6. Reaction between a maleimide and a thiol (Cys) 
 
 A question that remains to be answered regarding the PEGylated product is how 
the PEG behaves once attached. It is possible that the PEG could wrap around the protein 
like a rope, but more likely, the PEG would behave according to polymer theory, forming 
a spherical blob near the attachment point. In either case, the potential benefit of 
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attaching the PEG derives from its modification of the size, shape, and solubility of the 
protein being modified. 
 There are commonly proteolytic and immunogenic sites present on the solvent-
exposed portions of proteins, so if these proteins are to be used theranostically, these sites 
must either be engineered out or covered up. PEGs can do the latter, effectively 
eliminating sites where proteases might have otherwise cleaved the target protein and 
sites where elements of the human immune system might have recognized the protein as 
being foreign. Additionally, if a protein has solubility issues, adding a PEG, which is 
extremely soluble, could increase the solubility of said protein. One of the most important 
modifications PEGylation can create is in size. Filtration by the kidneys is largely based 
on size, so the time a potential theranostic protein spends in the blood, measured via 
serum half-life, can be affected by changing its size, in this case by attaching PEGs. 
Another factor important to kidney filtration is shape. PEGylation obviously affects this 
as well, and, as discussed before, the shape of PEGylated proteins is not immediately 
obvious. If the PEG wraps around the protein, its shape will remain similar to that of a 
single sphere; but if the PEG forms its own sphere near its attachment point, the shape of 
the protein is wildly changed as it is now more like a peanut, with two spheres next to 
each other.18-21 
 
1.5 Studying PEGylated Proteins 
 Largely, the aim of my research is to study the biophysical effects of PEGylating 
a protein. Obviously, to do this, various assays and techniques will be utilized. Many of 
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these are very simple and/or very common. Some, however, require some explanation. In 
order to measure the binding of a protein (in this case, an antibody fragment – but more 
on that later), a technique called surface plasmon resonance, or SPR, will be used. In this 
experiment, a ligand is bound with NHS-activation chemistry to a gold chip derivatized 
with dextran. A beam of light is focused onto the chip from the other side and has a 
certain angle of reflection. The target protein which binds to said ligand is then flowed 
over the chip at a constant rate. When the protein binds to the ligands bound to the chip, 
the angle of reflection of the light beam changes and this change is detected. The more 
protein that binds to the ligands bound to the chip, the greater the change of the angle of 
reflected light. In this way, the rate of association (the rate at which the protein binds to 
its ligand) can be measured using a program that fits the resulting curve to an equation. 
When nearing saturation, the protein ceases to be flowed over the chip, being replaced 
with a blank solution containing no protein. This allows the proteins already bound to the 
ligands on the chip to unbind, or dissociate. The angle of reflection changes again as 
protein dissociates, allowing the rate of dissociation to be measured as well. Using this 
association and dissociation data, the binding constant for the protein can be calculated. 
 In order to determine the shape via hydrodynamic radius, analytical 
ultracentrifugation, or AUC, can be used. In this technique, a solution containing a 
molecule of interest is centrifuged at high speed into a medium and the sedimentation is 
measured and can be equated to various aspects of the molecules size and shape. 
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Chapter 2: Objectives 
 
2.1 Expression and Purification of Proteins (3E8.scFv and 3E8cys.scFv) 
 In order to study PEGylation and how it might apply to RIGS, it would be 
convenient to use the actual molecule that will be utilized in the RIGS system, if the 
long-run goals are met. This way, the results of a rigorous study of PEGylation would 
overlap with the application of such PEGylation to the specific problem at hand, namely, 
to modifying the pharmacokinetic properties of an antibody fragment being used to detect 
and image cancer. Therefore, the expression and purification of both the actual protein 
being used (3E8.scFv) and of a version slightly modified to make PEGylation studies 
simpler (3E8cys.scFv), should be optimized to yield an acceptably high amount of active 
protein. 
 
2.2 Nonspecific PEGylation at Lysines and Characterization 
 Studying PEGylation via nonspecific modification using NHS-ester chemistry at 
multiple lysines is a good place to start because it is inexpensive and can be done on most 
proteins without modification. (This compared to specific PEGylation with maleimide 
chemistry, which requires free cysteines, a relatively rarer feature of proteins.) By 
nonspecifically PEGylating at lysines, the PEGylation procedure can be optimized and 
the general effects of PEGylation, particularly on stability and activity, can be observed 
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via various assays and experiments. There are confounding issues in these experiments, 
however, in that specific lysines might cause more problems than others. 
 
2.3 Specific PEGylation at Cysteines and Characterization 
 To more accurately characterize the effects of PEGylation, single PEGylation 
events must be isolated and studied in full before expanding to generalization about 
multiple PEGylation events, as in objective 2. Using specific and single PEGylation, 
comparisons between different types and sizes of PEGs can be made, specifically 
between 5, 20, and 40 kD PEGs, and between a linear and a Y-shaped branched PEG. 
These comparisons will hopefully shed some light on the structure-function relationships 
of PEGs and PEGylated protein conjugates. 
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Chapter 3: Methods 
 
3.1 Expression and Purification of Proteins (3E8.scFv and 3E8cys.scFv) 
Cytoplasmic Purification 
 The following expression/purification scheme is a modified version of a standard 
E. coli expression and immobilized metal ion affinity chromatography (IMAC) 
purification protocol.22 Following the same protocol for each, the following proteins were 
overexpressed in BL21(DE3) E. coli cells, unless stated otherwise: T4L, CC49, 
CC49.cyto (lacks a Pel-B leader sequence), 3E8.scFv, and 3E8cys.scFv. The genes for 
these proteins were in pCOLD or pHLIC, and during optimization, the E. coli strain was 
varied to C41(DE3), C43(DE3), NEB Xpress, DH10B(DE3), etc. Small 25 mL overnight 
cultures picked from colonies plated after transformation the day before were used as 
seeds for larger liquid cultures. These larger cultures were generally grown in 4 L non-
baffled flasks, containing 2 L of 2YT media, at 37 °C and shaken at 100-125 rpm (or 200 
rpm for T4L). For all proteins except T4L (for which this step was skipped), the flasks 
were then cold-shocked at log phase, or OD600 ≈ 0.75. This was accomplished either by 
swirling them in an ice bath or by letting them sit in the cold room at 4 °C (or both) for 
10-20 min. Then, the cultures were induced with IPTG to 0.05 mM (0.1 mM for T4L) 
and were kept at 4 °C for an additional 10-15 min. They were then allowed to continue 
growing overnight at 16 °C (T4L was grown for another 3 h at 37 °C). 
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 The cells were then centrifuged at 4 °C and 6000 rpm for 5 min and the pellets 
(sometimes frozen at -80 °C or -20 °C first, for storage) were resuspended in 20-25 mL 
lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole, pH 8) per liter of 
culture represented in the pellet. The resuspended cells were then mixed with 5mM 
MgCl2, 0.5 mM CaCl2, 5 µL of both DNase I and RNase A (at 5 mg/mL each) (per liter 
of culture represented), 0.1% Triton X-100, and 10-30 mg of HEW lysozyme (per liter of 
culture represented). This mixture was then allowed to incubate on ice/at 4 °C for at least 
30 min with agitation every 5 min or constant mixing via the mutator. The cells were then 
lysed with one or a combination of several methods: sonication, glass beads, and 
Emulsiflex. Sonication was performed at amplitude 7 by pulsing the resuspended pellet 4 
times at 30 sec each with 2 min breaks between pulses. The glass bead method was 
performed by adding about 0.5 mL of 0.1 mm glass beads (per liter of culture 
represented) to the resuspended pellet mixed with the lysing ingredients (as above) and 
vortexing for 3 min, 30 seconds at a time with 3 min on ice between pulses. The 
Emulsiflex was used to lyse cells by cycling the sample through the machine three times 
at a pressure differential of between 15,000 and 20,000 psi, keeping it on ice between 
cycles. 
 The lysate, once homogenous, was centrifuged at 4 °C and 15,000 rpm for 1 h. 
The supernatant was allowed to bind to 1 mL Ni-NTA agarose resin (Qiagen) per liter of 
culture for at least 30 min at 4 °C on the mutator. The mixture was then poured into a 
column (larger size, 20 mL), washed with wash buffer (20 mM imidazole), and eluted 
with elution buffer (250 mM imidazole). Between a 0.04 and 0.08 mg of TEV protease 
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was added to the elution twice; the first time, allowed to incubate overnight at room 
temperature and the second time, in the morning before continuing with the purification a 
few hours later, both times with 1 mM DTT. The resulting cleaved solution was desalted 
using a PD-10 column (GE Amersham) and swapped into TIM Storage Buffer (300 mM 
NaCl, 100 mM phosphate, pH 7.4) or lysis buffer. The buffer-swapped solution was then 
bound to 0.5 mL Ni-NTA per liter of culture the same as the first step. Another column 
was run (smaller size, 10 mL) and the flow-through was collected and kept as the 
cleaved, purified protein. The column was also washed with lysis buffer and/or dilutions 
of wash buffer and eluted with elution buffer. The flow-through was concentrated using 
Amicon Ultra 10,000 MWCO (Millipore) Centrifugal Filters and/or swapped into PBS 
buffer via dialysis (10,000 MWCO snakeskin or cassettes) as necessary. 
 
Periplasmic Purification and Modifications 
 This purification method was used on CC49.cyto (lacks a Pel-B leader sequence) 
and 3E8.scFv. It is identical to the normal cytoplasmic purification (above) up to the 
point of resuspending the pellets. Instead, the pellets in this method (Protocol 11. 
Preparation of 6xHis-tagged periplasmic proteins from E. coli, published by Qiagen) 
were resuspended in a buffer containing 30 mM Tris·HCl and 20% sucrose at pH 8.0 at a 
ratio of 80 mL per gram of wet weight in the pellet. Then, 500 mM EDTA was added 
incrementally, on ice. This mixture was then incubated on the mutator for 30 min and 
then centrifuged at 4 °C and 8,000 g for 20 min. The supernatant was decanted and saved 
(sucrose step) and the pellet was resuspended in the same volume of cold 5 mM MgSO4 
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and incubated on the mutator at 4 °C for 30 min. The mixture was again centrifuged the 
same as before and the supernatant was saved (MgSO4 step). The sucrose and the MgSO4 
steps supernatants were concentrated and then dialyzed into lysis buffer using cassettes. 
The purification then proceeded as above (Ni-NTA and column) but was stopped after 
the first column to assess yield. 
 Multiple modifications were made to this procedure to optimize yield. Certain 
things about the procedure were changed individually: EDTA was not added in one 
version, no dialysis was performed in another, and instead of relying on only osmotic 
shock to lyse the outer membrane, lysozyme was also employed in one version, which 
was further split into two experiments in which the osmotic shock was conducted before 
or after the first centrifugation step. 
 
3.2 Methods for Nonspecific PEGylation at Lysines and Characterization 
PEGylation at Lysines 
 Various PEGs with NHS-ester functional groups were stored at -20 °C in a 
tube/container with Drierite and were allowed to come to room temperature before being 
opened. The PEGylation procedure used was based on a procedure published by Thermo 
Scientific for PEGylating Proteins using NHS-PEGylation. Before the reaction takes 
place, the sample to be PEGylated should be dialyzed into PBS to avoid NHS-Tris 
reactions. A PEG stock solution of a certain concentration (calculated according to needs) 
was created by dissolving the appropriate amount of PEG in DMF. The appropriate 
amount of this stock solution to obtain the desired molar excess of PEG to protein was 
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then mixed with the protein solution (in PBS), being careful to keep the total amount of 
PEG solution under 10%, and preferably under 5%, if possible. The reason for this was 
that PEG was treated as potentially damaging to the protein’s fold at high concentrations. 
The total reaction volume was kept the same so the final concentration of the protein in 
every reaction remained constant. The reaction mixture was then mixed via vortexing and 
allowed to react at room temperature for 30 min-2 h depending on the desired extent of 
PEGylation. The reaction was then quenched with 100x excess (to the amount of PEG) of 
ethanolamine. 
 
EnzChek® Lysozyme Assay Kit 
 The EnzChek® Lysozyme Assay Kit by Molecular Probes (sold by Life 
Technologies) was used with T4L to assess activity after PEGylation to various degrees. 
The procedure laid out in the kit was followed very closely. First, a standard curve was 
produced by making lysozyme substrate and standard lysozyme (both included in the kit) 
stock solutions of 1.0 mg/mL and 1000 U/mL respectively in 1.0 mL deionized water 
each. The experimental samples of PEGylated lysozyme (T4L, produced following the 
cytoplasmic purification in objective 1, and PEGylated at various molar excesses 
according to the PEGylation procedure in objective 2) were diluted using the included 
reaction buffer (50 mL of 0.1 M sodium phosphate, 0.1 M NaCl, pH 7.5, and 2 mM 
sodium azide as a preservative). The standard lysozyme was serially diluted into 8 wells 
with the included reaction buffer. The stock substrate solution was diluted further to 
create a working substrate solution, which was then added to each of the wells containing 
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either standard or experimental lysozyme solutions. The plate containing the reaction 
mixtures was then incubated in the fluorescence microplate reader for 30 min at 37 °C 
while the reader took fluorescence readings with standard fluorescein filters for 
absorption maxima at 494 nm and fluorescence emission maxima at 518 nm. The 
background fluorescence was then subtracted out. 
 
Glycol Chitosan and the Imoto Assay 
 An alternative to the EnzChek® assay was discovered in da Silva Freitas’ paper23 
but was originally published in 1971 by Imoto and Yagishita.24 It assays lysozyme 
activity using the substrate glycol chitosan. It is performed my mixing 1 mL of 0.05% 
glycol chitosan in 100 mM pH 5.5 acetate buffer with 100 µL of lysozyme/modified 
lysozyme solution and incubating the mixture at 40 °C for 30 min. Then, 2 mL of the 
color reagent ([Fe(CN)6]3− dissolved in 0.5 M Na2CO3) was added and the mixture was 
boiled for 15 min. After cooling, the absorbance was read at 420 nm in a fluorimeter. 
  
Differential Scanning Fluorimetry (DSF)25 
 The PEGylated protein samples were mixed (19 µL) with 1 µL of the diluted 
SYPRO® Orange dye (Invitrogen) (provided as 5000x, diluted to 300x before addition, 
and then to 15x in the final mixture) in 96-well 0.2 mL thin-wall PCR plates (USA 
Scientific), sealed with Adhesive PCR Film (Thermo Scientific). Using a BioRad C1000 
Thermal Cycler, the temperature was increased by 0.2 °C every 12 s to acquire thermal 
denaturation curves, with the fluorescence intensities measured using a 490 ± 10 nm 
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excitation filter (from the SYBR Green set) and a 575 ± 10 nm emission filter (from the 
FRET filter set). Data were exported and analyzed in Microsoft Excel 2010/2013. 
 
Surface Plasmon Resonance (SPR) 
 The SPR performed was based on the literature for CC49.26,27 A CM5 chip was 
used in a Biacore T100. Scouting determined that 100 mM NaAc, pH 4 was a good 
immobilization buffer. BSM (positive for the Sialyl-Tn ligand) at 0.5 mg/mL and BSA 
(negative control) at 0.016 mg/mL were immobilized using the Amine Coupling kit 
(Pharmacia Biosensor), using N-ethyl-N-(3-diethylaminopropyl) carbodiimide (EDC) 
and NHS, quenching with ethanolamine/HCl (pH 8.5) and washing with 50 mM NaOH, 
until a surface of 700 resonance units was obtained, as per Pavlinkova et al.27 Then, 
binding analyses were performed in (HBS) buffer (10 mM (N-[2-
hydroxyethyl]piperazine-N'-[2-ethane sulfonic acid]) [HEPES] [pH 7.4], 0.15 M NaCl, 
3.4 µM EDTA, 0.005% surfactant P20) using the following parameters: samples were 
flowed over the chip for a contact time of 120 s, a flow-rate of 10 µL/min, and a 
dissociation time of 180 s; then the chip was regenerated with 6 M guanidine, 200 mM 
HOAc buffer with a 30 s contact time at a flow rate of 30 µL/min and a 0 s stabilization 
time. The range of concentrations used spanned from 5 nM to 400 nM, but the final set of 
concentrations that yielded the best results was 0, 5, 10, 25, 50, 75 (duplicate), 100, 150, 
and 200 nM. This range is suggested by the programming of the protocol on the software 
and is used to get a more accurate evaluation by taking into account the binding behavior 
at multiple concentrations. Once all the concentrations were run, the curves were fit using 
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the kinetics 1:1 global fit, over the whole series of concentrations, but changing the Rmax 
fit to local instead of global on the BIAevaluation 3.0 software (Biacore, Inc.) where the 
experimental design correlated with the Langmuir 1:1 interaction model.28 This yielded a 
ka, a kd, and from those, a KD. The Rmax values were also recorded for proper comparison. 
 
Circular Dichroism22 
 Data were collected on a Jasco J-815 CD spectrometer. TIM samples were diluted 
to 12 μM in 50 mM potassium phosphate and 300 mM NaCl, pH 8. Far-UV spectra were 
recorded in triplicate from 195 to 250 nm. Wavelength scans recorded ellipticity every 
nanometer with 2-s integration time and 100 nm·min−1 scanning speed. Data points 
reporting HT voltages greater than 600 V were discarded. For thermal denaturation, 
ellipticity was monitored at 222 nm with temperatures increasing from 25 to 95 °C. Data 
were collected in 1 °C steps with 6-s temperature equilibration, 1 °C min−1 ramping and 
2-s integration. Data were exported and analyzed in Microsoft Excel 2010/2013. 
 
3.3 Specific PEGylation at Cysteines and Characterization 
PEGylation at Cysteines 
 Specific PEGylation at cysteines using maleimide chemistry is performed 
similarly to nonspecific PEGylation at lysines using NHS-ester chemistry, described 
above, in objective 2 methods. Maleimide is not as liable to hydrolysis, however, so DMF 
does not need to be used: instead, the PEG stock solutions are made using PBS buffer. 
Again, the total volume of the reactions is kept the same so that the final concentration of 
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protein is the same for the various molar excesses and different PEGs. The reactions here 
take place overnight at room temperature and do not require quenching. Because the 
PEGs being used here were so much larger than the PEGs used for objective 2, the PEG 
stock solution, even though it contained no DMF, was still considered to be slightly 
organic because PEG is amphiphilic, and so was added in increments to the protein 
solution instead of all at once. 
 
Ion Exchange 
 An ÄKTApurifier 900-series FPLC using a 1 mL RESOURCE™ S column (GE 
Healthcare) was used for ion exchange. The low salt buffer used was 50 mM potassium 
acetate, 15 mM sodium chloride, pH 5 (buffer A) and the high salt buffer used was 50 
mM potassium acetate, 1 M sodium chloride, pH 5 (buffer B). A 1 mL loop was used and 
initially, a 200 column volume (CV) gradient (from 15 mM to 1 M NaCl) was set. During 
the runs, the flow rate was increased as long as the pressure limit was not exceeded. In 
addition, if it appeared that protein was not eluting (via a flat UV signal, between peaks), 
the gradient length was decreased to 20 CV to speed up the process. This was monitored 
very carefully and immediately increased back to 200 CV if anything appeared to be 
coming off the column (a rise in UV signal). 
 
Gel Filtration 
 The buffer used for gel filtration was 50 mM Tris, 100 mM NaCl, pH 8.0. The 
same FPLC used for ion exchange was also used here, but the column used was a 25 mL 
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Superdex™75 10/300 GL column (GE Healthcare). In this experiment, a 200 µL loop 
was used.  
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Chapter 4: Results and Discussion 
 
4.1 Expression and Purification of Proteins (3E8.scFv and 3E8cys.scFv) 
 Figure 7 shows an SDS PAGE Gel of a purification of T4L. FT2 and W2 are the 
final, purified protein in a high concentration. After TEV cleavage and a second Ni-NTA 
column, T4L is shown to be purified in high purity. It appears, however, that there could 
be a small molecular weight contaminant at the dye front. Consequently, if this was to be 
used for sensitive studies, further purification might have been needed. 
 
 
Figure 7. Gel of purification of T4L 
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 This protein was later used for nonspecific PEGylation experiments because of its 
13 surface lysines and one surface cysteine, shown in Figure 8, which also depicts the 
active site of T4L. 
 
 
Figure 8. T4L with orange/blue Lys, yellow/red Cys, and grey-green\red active site 
 
 Later, we had trouble reproducibly expression T4L, so we stopped using it in 
favor of the actual 3E8.scFv or 3E8cys.scFv for PEGylation experiments. 
 As described in the methods section, multiple modifications were made to the 
periplasmic purification method published by Qiagen. These modifications are described 
in Figure 9.  
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Figure 9. Periplasmic purification of 3E8.scFv: modifications and results 
 
 Figure 9 shows a number of modifications. The original periplasmic purification 
procedure published by Qiagen is represented by the blue boxes and arrows, and the 
results of that purification are shown in C and D. The dialysis step in this procedure was 
removed and this procedure is represented by the purple boxes and arrows, with the 
results shown in A and B. This modification resulted in less purified protein after the first 
Ni-NTA column, likely because the EDTA was not removed by dialysis, thereby 
allowing it to chelate some of the nickel in the Ni-NTA resin. Then, the EDTA was 
removed from the procedure all together along with the dialysis step, which was only 
there to remove the EDTA. Additionally, the 5 mM MgSO4 was only there to attempt to 
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sequester the EDTA, so with the EDTA removed, the MgSO4 was also removed. This 
procedure is represented by the green boxes and arrows, with the results shown in E and 
F. This was the best modification yet. The EDTA was originally used because it was 
thought to disrupt the membrane by sequestering calcium associated with the membrane. 
The membrane being disrupted meant that when the osmotic shock was performed, it 
would be easier for the protein of interest to exit the membrane. Evidently, EDTA was 
not necessary and in fact appears to have been detrimental to the purification. Instead of 
using EDTA to disrupt the outer membrane, then, (hen egg white) lysozyme was used, 
shown in the red box. This procedure was then split again, and in one branch, represented 
by the orange boxes and arrows, the osmotic shock was performed right away, followed 
by the rest of the procedure as normal. This resulted in the product labeled G, which was 
the most protein produced by any purification yet. Finally, the second branch using 
lysozyme to disrupt the membrane is represented in the red boxes and arrows, with the 
results labeled H and I. This procedure was similar to the orange procedure, but the 
original centrifugation step was added back in directly after letting the cells incubate in 
lysozyme. This was removed in the previous orange branch because it was thought – and 
confirmed – that any protein that had leaked out after disruption of the membrane would 
simply stay in solution after the osmotic shock and resulting spin. This is evidenced by 
the fact that it looks as if the product labeled G is about the same amount of protein in the 
products of H and I combined. Therefore, the “G” procedure was the “optimized” 
periplasmic purification procedure that was used until a better method – pHLIC in C43, 
lysis method – was discovered later. 
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 At this point, 3E8.scFv in pCOLD was being produced in BL21(DE3). The results 
of the various modifications are shown in Figure 9 and the modifications that produced 
the most protein, labeled F, G, H, and I, were further examined by conducting the TEV 
reaction as described in the methods, the results of which are shown in Figure 10. 
 
 
Figure 10. TEV cleavage of most promising samples from Figure 9 
 
 The final purification modification that was used to produce 3E8.scFv was the 
one labeled G, which followed the Qiagen method but did not add EDTA, instead adding 
hen egg white (HEW) lysozyme, before performing osmotic shock with water (instead of 
5 mM MgSO4). The rest of the purification was conducted the same way as the normal 
purification protocol described in methods. This “G” method was the preferred 
purification/expression scheme until different strains were tested and it was discovered 
that a similar amount of protein could be produced using the C43(DE3) strain with the 
gene in the pHLIC plasmid. 
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 Several other strains apart from BL21(DE3) were tested to see if the pCOLD 
plasmid could produce protein more effectively. Figure 11 shows the result of using 
DH10B(DE3) and NEB Express (New England BioLabs) E. coli cells with the original 
pCOLD plasmid and both 3E8.scFv and 3E8cys.scFv. Neither strain produced either 
protein any more efficiently than the BL21(DE3) cells did. 
 
 
Figure 11. Three E. coli strains’ production of 3E8.scFv and 3E8cys.scFv 
 
 At this point, the genes for 3E8.scFv and for 3E8cys.scFv were swapped into the 
pHLIC plasmid from the pCOLD plasmid and the C43(DE3) cell line was used to once 
again attempt to optimize production. Figure 12 shows the results of using C43(DE3) 
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cells to produce both 3E8.scFv and 3E8cys.scFv from the pHLIC plasmid. This 
combination of plasmid and cell line resulted in the best yield of either protein up to that 
point, and it was done via the cold shock method, but using the original complete cell 
lysis method, not the optimized osmotic shock method previously referred to as the “G” 
method. This purification scheme was then adopted for producing all 3E8.scFv and 
3E8cys.scFv. 
 
 
Figure 12. Expression of 3E8 fragments using pHLIC and C43 cells 
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4.2 Nonspecific PEGylation at Lysines and Characterization 
 The first attempt at nonspecific PEGylation at lysines using NHS-ester activated 
PEGs is shown in Figure 13. In this experiment, T4L was PEGylated with a 2 kD 
polydisperse NHS-ester PEG (Creative PEGWorks). The result of reactions using various 
molar excesses of PEG to T4L are shown. At lower excesses, bands above the band 
representing unPEGylated T4L start to appear in a stepwise fashion. These represent T4L 
molecules with integer numbers of PEGs attached. It can be seen that at higher excesses, 
the ladder of PEGylation products on the gel blend into a continuous smear. This could 
have something to do with large amounts of DMF or it could be a result of large amount 
of PEG binding to SDS at different charge-to-mass rations, resulting in a smear. 
 
 
Figure 13. Nonspecific PEGylation of T4L with polydisperse 2 kD NHS-ester PEG 
 
 This experiment was repeated (except with fewer molar excesses) in parallel with 
a very similar experiment, which used 1.8 kD discrete NHS-ester PEG (Quanta 
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BioDesign) instead of the 2 kD polydisperse PEG. Figure 14 shows the results of this 
experiment: a smear of bands on the left side (polydisperse PEG) like those that were 
seen in Figure 13, but a clear ladder of bands on the right side (discrete PEGs). This is 
likely due to the nature of polydisperse and discrete PEGs: the former are of an average 
size but have variation in the size of individual molecules, while the latter are all exactly 
the same molecular weight. 
 
 
Figure 14. Nonspecific PEGylation of T4L with 2 kD PEGs 
 
 Figure 15 shows the results of a repeat of the above experiment, PEGylating T4L 
with the same 1.8 kD discrete PEG (Quanta BioDesign), but at a wider range of molar 
excesses. (This was also repeated with the 2 kD polydisperse PEG as well, but the gel is 
not shown). It is indicated that a total of 14 bands above the unPEGylated T4L can be 
seen on the gel; there are 13 lysines in T4L, so the 14th band up represents T4L in which 
all 13 lysines and the amine group at the N-terminus are all PEGylated. 
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Figure 15. Nonspecific PEGylation of T4L with discrete 1.8 kD NHS-ester PEG 
 
 The samples shown in Figure 15 and discussed above, as well as the parallel 
samples PEGylated with the 2 kD polydisperse PEG, were characterized a variety of 
ways. The first, shown in Figure 16, was using the EnzChek® Lysozyme Assay Kit. 
Displayed as a bar graph, the fluorescence of each of the PEGylated T4L samples is 
shown and should be compared to that of the unPEGylated T4L sample, on the far right. 
 
 
Figure 16. EnzChek® assay showing relative activities of PEGylated T4L 
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 In this assay, fluorescence is proportional to activity. Somewhat predictably, the 
unPEGylated enzyme is the most active. Less predictable, however, is the nearly 
complete lack of fluorescence, and thus activity, of most of the PEGylated samples, 
particularly of the samples PEGylated with the discrete PEG. There is a general trend of 
less activity with greater molar excesses in the PEGylation reactions, i.e., with more 
attached PEGs per molecule. There are two immediately obvious explanations for this: 
either higher loads of PEGs ablate activity in general (either by unfolding the protein or 
by blocking the active site), or there are one or more specific lysines that, when 
PEGylated, result in a complete loss of activity. These two explanations are 
indecipherable using current data but this questions is being pursued by another 
undergraduate student in the Magliery Lab. If the latter is the case, then the level of 
fluorescence seen would correlate to the amount of unPEGylated T4L seen in each 
sample. In the gels shown in Figure 16, especially in the polydisperse PEGylation gel, it 
is clearly seen that there was some amount of unPEGylated T4L that decreased as the 
molar excess of PEG was increased. This is less true with the discrete PEGylation, which 
appears to PEGylate more effectively, thereby leaving less T4L unPEGylated, which 
would result in less activity overall, for every sample. These trends, predicted by the 
explanation that PEGylating a certain lysine or lysines kill activity by itself, are what is 
indeed seen in Figure 16. The activity seems to be related to the amount of unPEGylated 
material. 
 In order to further investigate the above conundrum, a CD scan was acquired of 
selected PEGylated samples of T4L (same as above), along with an unPEGylated sample 
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and with simple solutions of PEGs, unattached to anything. Shown in Figure 17, the 
unPEGylated T4L sample produced a fine spectrum, but the other samples all exceeded 
the dynode voltage due to PEG’s strong absorbance and thus, beyond that point, the 
spectra were inaccurate and not presented. No information was gleaned from this 
experiment and other characterizations were pursued because this was the point where it 
was discovered that the EnzChek® Assay might not accurately report on all types of 
Lysozyme activity. 
 
 
Figure 17. CD scans of PEGylated T4L of raw PEGs 
 
 The Imoto assay, described in the Methods section, is another lysozyme activity 
assay which works by measuring the disappearance of absorbance at 420 nm (yellow 
color) of a colorimetric reagent, [Fe(CN)6]3−, that reacts with the digested substrate, 
glycol chitosan, eliminating its absorbance/color. The assay was shown to work when, as 
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a control, HEW lysozyme was used according to the protocol at different concentrations. 
These results in Figure 18 show a decrease in absorbance at 420 nm with increasing 
concentration of HEW lysozyme.  
 
 
Figure 18. Imoto assay performed on hen egg white lysozyme standards 
 
 The experiment was then performed on T4L, with unPEGylated and PEGylated 
samples. Figure 19 shows that, basically, all of the signals are in the background noise, 
i.e. none of the samples showed any appreciable activity. This could be because the 
concentrations of the samples of T4L were too low and thus not enough substrate was 
Increasing HEW 
Concentration 
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turned over to show any decrease in absorbance at 420 nm, or because the substrate, 
glycol chitosan, is not digestible by T4L. 
 
 
Figure 19. Imoto assay performed on T4L, PEGylated and not 
 
 In an attempt to decipher the meaning of this results of the Imoto assay, it was 
slightly modified so that it was performed under conditions similar to the EnzChek® 
Assay (40 °C was changed to 37 °C and the reaction buffer was changed to that of the 
EnzChek® Assay) while the EnzChek® Assay itself was repeated in parallel. Figure 20 
shows that while T4L does not produce as much fluorescence as HEW lysozyme, it still 
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shows enough fluorescence over the background that its activity is not in question via the 
EnzChek® Assay. 
 
 
Figure 20. Repeat of EnzChek® assay; shows T4L activity 
 
 However, in the modified Imoto procedure, the results of which are shown in 
Figure 21, once again, the depletion of absorbance at 420 nm by any T4L sample, i.e. the 
activity, is not appreciable/is in the background, while the same HEW lysozyme samples 
show remarkable depletion of absorbance at 420 nm. This experiment did nothing to 
decipher the results of the pure Imoto procedure, but it proved that it works for active hen 
egg white lysozyme samples. 
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Figure 21. Repeat of Imoto assay under EnzChek conditions 
 
 The nature of T4L’s limited response in the Imoto assay, whether due to inactivity 
against glycol chitosan or due to a low concentration, was not investigated further 
because at the time of this final experiment, it was discovered that 3E8.scFv and 
3E8cys.scFv could be produced at a high enough level using pHLIC and C43(DE3), 
meaning that T4L had no further use as a model protein for PEGylation studies. 
 3E8.scFv was first nonspecifically PEGylated at lysines with the same 1.8 kD 
discrete PEG as before. The lysines of 3E8.scFv are depicted in Figure 22 in orange with 
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the CDR, or binding site, shown in purple. Only the 12 lysines not in the linker are 
shown. More lysines exist in the peptide linker, but are not shown. 
 
 
Figure 22. 3E8.scFv with orange/blue Lys and purple CDR 
 
 Figure 23 shows that, for the purposes of a study of various types and sizes of 
PEGs, 2x molar excess produced what was designated to be the “low” average number of 
attached PEGs while 16x molar excess produced what was designated to be the “high” 
average number of attached PEGs. 
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Figure 23. Nonspecific PEGylation of 3E8.scFv with 1.8 kD discrete NHS-ester PEG 
 
 A set of six different PEGs was chosen and is shown in Figure 24. Each PEG was 
given a letter as a label. PEGs B, D, E, F, and X were discrete PEGs with the shown 
molecular weights (Quanta BioDesign), while PEG Y was the same 2 kD polydisperse 
PEG (Creative PEGWorks) as before. (PEG X was the same discrete PEG used before as 
well.) 
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Figure 24. Six NHS-ester PEGs of various size, shape, and charge 
 
 Each PEG above was reacted with 3E8.scFv at 2x and 16x molar excess (low 
load, or “L,” and high load, or “H,” respectively), keeping the total volume and final 
concentration of 3E8.scFv the same in every reaction. The results of these PEGylations, 
after dialysis, are shown in Figure 25. (The sample that was PEGylated with PEG Y at 
high load was lost in the dialysis step due to a hole in the dialysis cassette.) 
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Figure 25. Nonspecific PEGylation of 3E8.scFv with the six PEGs from Figure 16 
 
 The samples shown in Figure 25 were then characterized using DSF. Differential 
scanning fluorimetry, or DSF, uses SYPRO® Orange dye, which, when exposed to a 
hydrophobic environment, fluoresces. In DSF, protein samples are heated up, causing 
them to unfold. The cores of proteins very often contain many hydrophobic residues, and 
so, as proteins are heated up and unfolded, more and more hydrophobic residues are 
exposed to solution. Therefore, as the samples are heated up, SYPRO® Orange binds to 
more and more hydrophobic residues and increasingly fluoresces, resulting in a higher 
signal. Figures 26 and 27 show the DSF melting curves of the PEGylated 3E8.scFv 
samples at low loads and at high loads, respectively. All of the samples PEGylated at low 
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loads appear to melt at the same temperature as unPEGylated 3E8.scFv, shown in the 
thick black line, and thus the stability of 3E8.scFv is not decreased with low levels of 
PEGylation. At high PEGylation loads, however, all of the samples have lower melting 
temperatures than unPEGylated 3E8.scFv, indicating that higher loads of PEGylation 
actually decrease the stability of 3E8.scFv by a small amount. 
 
 
Figure 26. DSF spectrum of 3E8.scFv PEGylated at low load 
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Figure 27. DSF spectrum of 3E8.scFv PEGylated at high load 
 
 Surface plasmon resonance, or SPR, was then used to characterize the effects of 
PEGylation on the binding of 3E8.scFv to the proper substrate, Sialyl-Tn. Example SPR 
spectrograms are shown in Figures 28 and 29, which show the binding behavior of the 
low and high load PEGylated samples (respectively) using PEG X, the 1.8 kD discrete 
PEG. The corresponding lane from the gel in Figure 23 is shown in the upper right corner 
of each Figure. The different traces, color-coded, represent different concentrations of 
sample that were run. These were suggested by the programmed protocol. 
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Figure 28. SPR of 3E8.scFv PEGylated with PEG X at low load 
 
 
Figure 29. SPR of 3E8.scFv PEGylated with PEG X at high load 
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 The results of the SPR experiment for all of the PEGylated samples are shown in 
Table 1. Similarly to the trend in stability with PEGylation loads, the trend in binding 
activity seems to be that at higher loads of PEG, 3E8.scFv loses much, if not all, of its 
binding affinity. 
 
 
Table 1. KD values of 3E8.scFv PEGylated at low and high load with various PEGs 
 
 The same confounding question about whether high loads of PEGylation in 
general ablates activity/binding or whether specific lysines that have a great effect on 
activity/binding are more likely to be PEGylated at high loads that was present in the T4L 
PEGylation experiments is present again in these DSF and SPR PEGylation experiments. 
As previously stated, this issue is being pursued further, but in an attempt to get some 
definitive information about what PEGylation does to binding and stability, specific 
PEGylation using maleimide chemistry and cysteine residues was pursued using 
3E8cys.scFv. 
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4.3 Specific PEGylation at Cysteines and Characterization 
 Once it was known that using the pHLIC plasmid in the C43(DE3) strain could 
produce a moderate amount of 3E8cys.scFv, it started being produced in mass quantities 
so that PEGylation could be studied in isolation, via single PEGylation at the added free 
cysteine, which is depicted in Figure 30, in red. 
 
 
Figure 30. 3E8cys.scFv with red/yellow C-terminal free Cys and purple CDR 
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 In order to get the sizes of PEG desired, polydisperse PEGs had to be used 
because Quanta BioDesign does not routinely synthesize PEGs larger than about 10 kD. 
The series of PEGs that was used was designed to study the differences in size and in 
shape, so maleimide PEGs of 5 kD, 20 kD, and 40 kD were used (JenKem Technology 
USA). All of these were linear PEGs (the normal configuration), but in addition, a 40 kD 
Y-shaped branched PEG was also used (JenKem Technology USA), a picture of which is 
shown Figure 31. 
 
 
Figure 31. Basic Structure of Y-shaped PEG from JenKem 
 
 Four samples of 3E8cys.scFv were PEGylated at 50x molar excess overnight at 
room temperature with each of the four PEGs mentioned above. Additionally a control 
sample, labeled “ctrl,” was treated the same way as the PEGylated samples but no PEG 
was added, only buffer. The initial gel is shown in Figure 31. Large PEGs do not run well 
on SDS-PAGE gels because SDS does not bind well to them, so it is difficult to see the 
extent of PEGylation in Figure 31. 
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Figure 32. Specific PEGylation of 3E8cys.scFv with four maleimide PEGs 
 
 The PEGylation samples were buffer swapped into 50 mM potassium acetate 
buffer in order to perform ion exchange. The elution profiles of the five samples from ion 
exchange are shown in Figures 32-36, and the fractions combined as the purified product 
are indicated with the red boxes. 
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Figure 33. Ion exchange (IEX) elution profile of unPEGylated 3E8cys.scFv 
 
 
Figure 34. IEX elution profile of 3E8cys.scFv PEGylated with 5 kD PEG 
 
  
62 
 
 
Figure 35. IEX elution profile of 3E8cys.scFv PEGylated with 20 kD PEG 
 
 
Figure 36. IEX elution profile of 3E8cys.scFv PEGylated with linear 40 kD PEG 
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Figure 37. IEX elution profile of 3E8cys.scFv PEGylated with Y-shaped 40 kD PEG 
 
 After the fractions were recombined, they were concentrated down to around 1 
mL using the same concentrators as mentioned in methods and buffer swapped into PBS 
using NAP 10 columns. The purified and concentrated samples were then run on a gel to 
determine concentration by comparison to the known concentrations of protein in the 
ladder: the 50 kD band is 1 µg and the 35 and 25 kD bands are each ½ µg. The gel is 
shown in Figure 37. 
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Figure 38. Gel of IEX purified PEGylated 3E8cys.scFv samples 
 
 Gel filtration was then performed on the five samples, injecting 200 μL of each. 
The results, shown in Figure 38, indicate that each of the five samples appear to be 
monomers. The apparent molecular weights are inaccurate, however, likely due to the 
fact that the standard curve was calculated using the elution profiles of globular, spherical 
proteins, whereas 3E8cys.scFv is more complicated than that, in addition to the fact the 
PEGs are less dense than protein, meaning PEG-protein conjugated will have a larger 
volume than an equivalent molecular weight of pure protein. 
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Figure 39. Gel filtration elution profiles of PEGylated 3E8cys.scFv 
 
 The DSF profile of the five samples, shown in Figure 39, was rather unexpected 
and difficult to decipher. The presence of the first transition, which is seemingly visible 
in the unPEGylated samples but accentuated in the PEGylated samples (with the 
exception of the samples PEGylated with the 5 kD PEG), is somewhat of a mystery. It 
could represent the dissociation of the two domains of the antibody fragment while the 
second transition, which is what we consider to be the main transition for the 
unPEGylated 3E8cys.scFv and 3E8.scFv, could represent the unfolding of the individual 
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domains in the proteins. Additionally, the first transition could represent some interaction 
between the PEGs and the dye. It’s origin is currently unknown. 
 
 
Figure 40. DSF melting profiles of PEGylated 3E8cys.scFv 
 
 SPR was also performed on samples prepared before those analyzed above, the 
results of which are shown in Table 2. UnPEGylated 3E8cys.scFv was shown to have a 
KD of around 40 nM and 3E8cys.scFv samples PEGylated with the same 40 kD linear 
and Y-shaped PEGs as above were shown to not have decreased binding. 
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Table 2. KD values of 3E8cys.scFv and two PEG conjugates 
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Conclusions and Future Directions 
 
 T4L was used as a preliminary model for 3E8.scFv. It was produced at high yield 
and was then nonspecifically PEGylated. The resulting PEG conjugates were tested for 
activity using the EnzChek® Lysozyme Assay Kit. The assay worked but the results were 
not conclusive. It appeared that the activity of each of the PEGylated samples 
corresponded to the amount of unPEGylated T4L in each sample. This observation lead 
to the thought that any amount of PEGylation was detrimental to binding. In an attempt to 
remedy this, a different lysozyme activity assay, discussed as the Imoto assay, was 
attempted. This assay worked on the standard HEW lysozyme samples but not on any 
T4L samples, leading to the conclusion that the substrate being used was not a viable 
substrate for T4L. At this point, the expression and purification of 3E8.scFv and 
3E8cys.scFv was optimized and T4L as s model protein was no longer needed. 
3E8.scFv, previously extensively characterized and now being produced in 
reasonable high yields, was then PEGylated nonspecifically as T4L had been. The 
resulting PEG conjugates were studied for binding activity via SPR and for stability via 
DSF. SPR revealed that low loads of PEGylation (an average of around one or two PEGs 
per molecule) did not affect binding much, if at all, while higher loads of PEGylation (an 
average of about five attached PEGs per molecule) resulted in an almost complete 
ablation of binding. DSF revealed that low loads of PEGylation did not affect stability 
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much, if at all, while higher loads seemed to decrease the melting temperature by a few 
degrees. These results were somewhat difficult to interpret because exactly which lysines 
were PEGylated was not knowable based simply on SDS-PAGE analysis. It could be, for 
example, that the PEGylation of a specific lysine in the binding site was responsible for 
the complete ablation of binding while PEGylating every other lysine would have no 
effect on binding. In order to eliminate some of these variables and to study PEGylation 
in a more pure form, a version of 3E8.scFv with an extra free cysteine engineered onto 
the C-terminus, called 3E8cys.scFv, was to be used. 
3E8cys.scFv was also being produced in high yields at this point, so it was an 
easy transition to PEGylating this version of 3E8.scFv. It was PEGylated specifically at 
the free cysteine using maleimide PEGs. This meant that only a single PEG, of known 
size, was attached to each 3E8cys.scFv molecule after the PEGylation reaction. This 
removed the question of which residues might have been preferentially PEGylated and 
allowed a more comprehensive study on PEGylation as a modification. Previous SPR 
results indicated no decrease in binding when a single 40 kD PEG (linear or Y-shaped) 
was attached. Gel filtration showed that four samples of 3E8cys.scFv each singly 
PEGylated with one of a 5 kD, a 20 kD, a linear 40 kD, and Y-shaped 40 kD PEG were 
all still monomers with no aggregation. DSF scans of these PEGylated samples showed 
an interesting unfolding profile with a large transition that grew in before the original 
unfolding transition in the spectrum of 3E8cys.scFv. The nature of this is unknown but it 
could represent the dissociation of the two domains of 3E8cys.scFv before the unfolding 
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of the individual domains. Whatever it is, it appears that single PEGylation at the C-
terminus with large PEGs (greater than 20 kD) changes how 3E8cys.scFv unfolds. 
 Future work entails finishing the biophysical characterization of the singly 
PEGylated 3E8cys.scFv samples with AUC, DSLS, and potentially SAXS. AUC 
measures sedimentation and will help to describe the shape of 3E8cys.scFv and its PEG 
conjugates by providing a hydrodynamic radius. DSLS is another stability study which 
relies upon aggregation of the protein of interest, measuring the amount of light that is 
transmitted through a protein sample being heated. However, because PEGs are thought 
to prevent or delay aggregation, this assay might simply reveal the aggregation 
characteristics of 3E8cys.scFv-PEG conjugates. SAXS is a structural technique which 
will reveal information about the size and shape of proteins by measuring how x-rays 
scatter at very small angles after being directed at the protein of interest. Specifically, this 
technique will be used to determine whether PEGs wrap around 3E8cys.scFv, which 
would result in a roughly spherical shape with little change in shape from the 
unPEGylated protein, or whether PEGs form a polymer-like bead near their attachment 
point, which would result in a “peanut” shape, more like two spheres next to each other.  
Additionally, the nature of which of the lysines of 3E8.scFv are important in the 
realm of PEGylation will be investigated. To do this, several lysines which, if PEGylated, 
might cause a problem with the activity/binding of the protein (i.e. they are near the 
binding site), have been mutated individually to arginines. If any of these single mutants 
display binding activity, they will be PEGylated in a fashion similar to the nonspecific 
PEGylation studies presented in this thesis. If the resulting PEG conjugates still bind, the 
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mutated lysine could have been the problem. Additionally, a study to determine which 
lysines are being PEGylated (and hopefully, to determine in what order) will be 
conducted using some PEG-biotin derivative, a trypsin digest, and mass spectrometry. 
This will indicate which lysines are PEGylated in a nonspecifically PEGylated sample, 
and potentially, which lysines are preferentially PEGylated/PEGylated first (potentially 
due to activation).  
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